%{{tag.tag}} {{articledata.title}} {{moment(articledata.cdate)}} @{{articledata.company.replace(" ","")}} comment With a focus on developing Generative %AI and Machine Learning solutions targeted at the %Pharmaceutical industry, this company is launching a new offering to improve clinical trials. %NetraMarkHoldings (CSE: AIAI) (OTC: AINMF), a generative AI software leader in clinical trial solutions, announced in a press release today the launch of its NetraAI Lab. The offering is designed to make it easier and more affordable for biopharmaceutical companies to experience the benefits of how its NetraAI solution can improve clinical trial success rates. Through this offering, NetraMark will apply NetraAI to customers' clinical trial data and seek to identify key variables that drive specific trial outcomes, provide testable hypotheses about the role that these variables play in patient responses and recommend inclusion and exclusion criteria based on these insights that can potentially be used to improve the success of future clinical trials.